<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1797">
  <stage>Registered</stage>
  <submitdate>11/01/2008</submitdate>
  <approvaldate>11/01/2008</approvaldate>
  <nctid>NCT00599274</nctid>
  <trial_identification>
    <studytitle>Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis</studytitle>
    <scientifictitle>A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX速 and Rebif速 to Determine the Efficacy, Tolerability, and Safety in Subjects With Relapsing Multiple Sclerosis (MS)</scientifictitle>
    <utrn />
    <trialacronym>PROOF</trialacronym>
    <secondaryid>C-862</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Interferon beta-1a
Treatment: drugs - Interferon beta-1a

A - This group was treated with Avonex once a week

B - This group was treated with Rebif three times a week


Treatment: drugs: Interferon beta-1a
injection once a week

Treatment: drugs: Interferon beta-1a
injection three times a week

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Must have been receiving AVONEX速 or Rebif速.

          -  Must have a confirmed diagnosis of relapsing-remitting MS using the Poser criteria.

          -  Must have experienced at least 2 relapses within the 3 year period prior to the
             initiation of treatment.

          -  Must have an EDSS score of 0.0 to 5.5, inclusive.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of severe allergic or anaphylactic reaction or hypersensitivity to human
             albumin, to any interferon, or to other components of the drug formulation.

          -  History of poorly controlled hypertension and/or other clinically significant major
             disease.

          -  History of uncontrolled seizures within the 3 months prior to enrollment.

          -  History of suicidal ideation or an episode of severe depression within the 3 months
             prior to enrollment.

          -  Serious local infection or systemic infection within 8 weeks prior to enrollment.

          -  Treatment with certain other agents to treat MS symptoms or underlying disease.

          -  Treatment with any investigational product

          -  Previous participation in this study.

          -  Other Protocol-defined inclusion/exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>136</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2003</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Coordinating Research Site - Woodville</hospital>
    <postcode> - Woodville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to find out if weekly Avonex works as well as three times a week
      Rebif in subjects with relapsing multiple sclerosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00599274</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Biogen-Idec Investigator</name>
      <address>Biogen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>